In essence, our data indicate that TRAF3IP2 is a tumor-derived factor that is important for tumor progression in NONO-TFE3 tRCC, uncovering a new regulatory mechanism that drives tumor progression. This evidence concerns the gene TRAF3IP2 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.